Fulcrum Therapeutics (FULC) News Today $3.22 +0.25 (+8.42%) (As of 01:24 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from BrokeragesFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received an average rating of "Hold" from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and threeNovember 20 at 5:47 AM | marketbeat.comHC Wainwright Has Positive Outlook for FULC FY2024 EarningsNovember 20 at 2:09 AM | americanbankingnews.comResearch Analysts Issue Forecasts for FULC FY2024 EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at HC Wainwright raised their FY2024 EPS estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the company will postNovember 18, 2024 | marketbeat.comSimplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Simplify Asset Management Inc. reduced its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 47.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 351,314 shares of the company's stock after selling 323,518 sharesNovember 15, 2024 | marketbeat.comCautious Hold Rating on Fulcrum Therapeutics Amid Uncertain Prospects and Strategic ShiftsNovember 15, 2024 | markets.businessinsider.comFulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)November 15, 2024 | finance.yahoo.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.comFulcrum Therapeutics' (FULC) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "neutral" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday.November 14, 2024 | marketbeat.comFulcrum Therapeutics expects cash to fund operations into at least 2027November 14, 2024 | markets.businessinsider.comFulcrum Therapeutics Reports Q3 2024 Financial ProgressNovember 14, 2024 | markets.businessinsider.comFulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comFulcrum Therapeutics to Participate in the Stifel Healthcare ConferenceNovember 12, 2024 | globenewswire.comFulcrum Therapeutics (FULC) Scheduled to Post Earnings on WednesdayFulcrum Therapeutics (NASDAQ:FULC) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comFulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ETNovember 6, 2024 | globenewswire.comAssenagon Asset Management S.A. Has $1.22 Million Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Assenagon Asset Management S.A. reduced its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 31.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 340,495 shares of the company's stockNovember 2, 2024 | marketbeat.comShort Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Decreases By 6.4%Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 5,520,000 shares, a decline of 6.4% from the September 30th total of 5,900,000 shares. Based on an average daily volume of 1,650,000 shares, the days-to-cover ratio is currently 3.3 days.October 31, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from AnalystsShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have received a consensus recommendation of "Hold" from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold ratiOctober 26, 2024 | marketbeat.comWe're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To GrowOctober 21, 2024 | finance.yahoo.comAvidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats UpOctober 18, 2024 | msn.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 11, 2024 | globenewswire.comFulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...October 9, 2024 | finance.yahoo.comFulcrum Therapeutics Sees Unusually High Options Volume (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw unusually large options trading on Wednesday. Stock investors purchased 30,075 call options on the company. This represents an increase of approximately 1,522% compared to the typical volume of 1,854 call options.October 9, 2024 | marketbeat.comDimensional Fund Advisors LP Has $9.18 Million Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Dimensional Fund Advisors LP increased its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 13.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,480,926 shares of the company's stock aftOctober 8, 2024 | marketbeat.comFMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc SharesOctober 7, 2024 | gurufocus.comPetri Dish: IPO-bound drugmaker strikes BioMarin deal, plus other biotech newsOctober 3, 2024 | bizjournals.comHealthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it mattersOctober 1, 2024 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Hold" by AnalystsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has earned an average rating of "Hold" from the ten research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buyOctober 1, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Growth in Short InterestFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 11,400,000 shares, a growth of 41.4% from the August 31st total of 8,060,000 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently 6.8 days.September 29, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock, Insider Trading ActivitySeptember 27, 2024 | benzinga.comFulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market OpportunitySeptember 27, 2024 | marketwatch.comFulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setbackSeptember 27, 2024 | msn.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 25, 2024 | globenewswire.comFulcrum Therapeutics to Cut 29 Jobs Amid Reprioritization of R&DSeptember 24, 2024 | marketwatch.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 23, 2024 | prnewswire.com186,727 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Bought by Bank of New York Mellon CorpBank of New York Mellon Corp bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 186,727 shares of the compaSeptember 21, 2024 | marketbeat.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 19, 2024 | globenewswire.comBrokers Issue Forecasts for Fulcrum Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, September 12th. Leerink Partnrs analyst J. Schwartz now anticipates that theSeptember 16, 2024 | marketbeat.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 15, 2024 | prnewswire.comRBC Capital Downgrades Fulcrum Therapeutics (FULC)September 15, 2024 | msn.comBuy Rating on Fulcrum’s Losmapimod: Navigating FSHD Treatment Potential Despite Phase 2 ChallengesSeptember 13, 2024 | markets.businessinsider.comStifel Downgrades Fulcrum Therapeutics (FULC)September 13, 2024 | msn.comB of A Securities Downgrades Fulcrum Therapeutics (FULC)September 13, 2024 | msn.comHold Rating on Fulcrum Therapeutics Amid Phase 3 Drug Failure and Pivot to Sickle Cell Disease CandidateSeptember 13, 2024 | markets.businessinsider.comBreaking Down Fulcrum Therapeutics: 7 Analysts Share Their ViewsSeptember 13, 2024 | benzinga.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 13, 2024 | globenewswire.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 13, 2024 | globenewswire.comFulcrum Therapeutics (NASDAQ:FULC) Downgraded to Neutral at HC WainwrightHC Wainwright lowered Fulcrum Therapeutics from a "buy" rating to a "neutral" rating and decreased their target price for the company from $17.00 to $4.00 in a research report on Friday.September 13, 2024 | marketbeat.comFulcrum downgraded after setback for lead program (update)September 13, 2024 | msn.comFulcrum Therapeutics (NASDAQ:FULC) Downgraded by Royal Bank of Canada to Sector PerformRoyal Bank of Canada cut Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price objective for the stock from $15.00 to $4.00 in a report on Thursday.September 12, 2024 | marketbeat.comFulcrum's muscle disorder drug fails in late-stage studySeptember 12, 2024 | reuters.com Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. FULC Media Mentions By Week FULC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼0.640.48▲Average Medical News Sentiment FULC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼74▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BLUE News Today KZR News Today SGMO News Today EXAI News Today CRMD News Today STOK News Today ALT News Today DNTH News Today OCS News Today IMNM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe #1 Bitcoin ETF For Monthly DividendsYou don't have to own any Bitcoin to collect BIG dividends from it... Now, thanks to this brand new Bitcoin...Investors Alley | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | SponsoredThe AI Crash Begins November 30thMost AI stocks are doomed. I’m not an AI hater. AI will absolutely continue to be the most disruptive tech...Brownstone Research | SponsoredFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most import...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredTrump Won, But Can He Save Your 401(k)?Trump Won, But Your Savings Are Still In Danger It's the ONLY playbook that shows you how to fortify your f...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
